Claims for Patent: 8,143,237

Summary for Patent: 8,143,237

Title:	Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
Abstract:	Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): ##STR00001## wherein the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.6, and R.sup.7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing\'s sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.
Inventor(s):	Gokaraju; Ganga Raju (Vijayawada, IN), Kasina; Sudhakar (Mercer Island, WA), Gokaraju; Rama Raju (Vijayawada, IN), Gokaraju; Venkata Kanaka Ranga Raju (Vijayawada, IN), Somepalli; Venkateswarlu (Vijayawada, IN), Golakoti; Trimurtulu (Vijayawada, IN), Bhupathiraju; Kiran (Vijayawada, IN), Krishanu; Sengupta (Vijayawada, IN), Alluri; Venkata Krishna Raju (Vijayawada, IN)
Assignee:	Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN)
Application Number:	12/767,647
Patent Claims:	1. A compound of formula (I) having a selenophene ring or a pharmaceutically acceptable salt thereof: ##STR00036## wherein: R is selected from H, CH.sub.3 and CH.sub.2OH; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from the group consisting of H, N.dbd.N--N(CH.sub.3).sub.2, N.dbd.N--NHCH.sub.3, N.dbd.NN(CH.sub.3)CH.sub.2OH, CONH.sub.2, CONHR.sup.4, CONR.sup.4R.sup.5, CONHNH.sub.2, CONHNHR.sup.4, CONHNR.sup.4R.sup.5, COOCH.sub.3, COOCH.sub.2CH.sub.3, COON, COSH, CN, C.ident.CH, SO.sub.2NH.sub.2, SO.sub.2NHR.sup.4, SO.sub.2NR.sup.4R.sup.5, NO.sub.2, CF.sub.3, Cl, Br, F, CCl.sub.3, CH.sub.3, OH, OCH.sub.3, SH, SCH.sub.3, NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, alkyl, alkenyl, electron withdrawing functional groups and electron donating functional groups, wherein R.sup.4 and R.sup.5 are independently selected from the group consisting of H, CH.sub.3, C.sub.1-C.sub.10 alkyl, alkenyl, alkylol, alkoxy, and alkylamine; or wherein any two of R.sup.1, R.sup.2 and R.sup.3 are joined together to form a ring selected from the group consisting of an alicyclic, aromatic, or heterocyclic ring system which is fused to two adjacent carbon atoms in said selenophene ring. 2. The compound of claim 1, wherein any two of R.sup.1, R.sup.2 and R.sup.3 are selected from the group consisting of said alicyclic, aromatic, or heterocyclic ring system, said ring system being a cyclopentyl ring, a cyclohexyl ring, a phenyl ring or a pyridyl ring. 3. The compound of claim 1, wherein said compound is selected from the group consisting of: a) 4-[(dimethylamino)diazenyl]-5-methylselenophene-2-carboxamide; b) 3-[(dimethylamino)diazenyl]selenophene-2,5-dicarboxamide; c) 3-[(dimethylamino)diazenyl]-5-phenylselenophene-2-carboxamide; d)3-[(dimethylamino)diazenyl]-5-(tert-butyl)selenophene-2-carboxamide; e) 3-[(dimethylamino)diazenyl]-4,5,6,7-tetrahydrobenzo[1,2-b]selenophene-2-c- arboxamide; f) 3-[(dimethylamino)diazenyl]selenopheno[2,3-b]pyridine-2-carboxamide; g) 3-[(dimethylamino)diazenyl]-5-phenylselenophene-2-carboxylic acid; h) 3-[(dimethylamino)diazenyl]-5-(tert-butyl)selenophene-2-carboxylic acid; i) 3-[(dimethylamino)diazenyl]-4,5,6,7-tetrahydrobenzo[1,2-b]selenophene-- 2-carboxylic acid; j) 3-[(dimethylamino)diazenyl]selenopheno[2,3-b]pyridine-2-carboxylic acid; and k) 3-[(dimethylamino)diazenyl]-5-(tert-butyl)selenophene-2-carbonitri- le. 4. A compound of formula (II) having a selenophene ring or a pharmaceutically acceptable salt thereof: ##STR00037## wherein: the notation represents a single bond or a double bond; X, Y and Z are independently selected from C and Se so as to form a selenophene ring, with the proviso that a double bond is either in between X and Y or in between Y and Z; R.sup.6 and R.sup.7 are either: a) independently selected from H, N.dbd.N--N(CH.sub.3).sub.2, N.dbd.N--NHCH.sub.3, N.dbd.N--N(CH.sub.3)CH.sub.2OH, CONH.sub.2, CONHR.sup.8, CONR.sup.8R.sup.9, CONHNH.sub.2, CONHNHR.sup.8, CONHNR.sup.8R.sup.9, COOCH.sub.3, COOCH.sub.2CH.sub.3, COOH, COSH, CN, CECH, SO.sub.2NH.sub.2, SO.sub.2NHR.sup.8, SO.sub.2NR.sup.8R.sup.9, NO.sub.2, CF.sub.3, Cl, Br, F, CCl.sub.3, CH.sub.3, OH, OCH.sub.3, SH, SCH.sub.3, NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, alkyl, alkenyl, electron withdrawing functional groups, and electron donating functional groups; or b) joined together to form an alicyclic, aromatic, or heterocyclic ring system which is fused to two adjacent carbon atoms in said selenophene ring; and R.sup.8 and R.sup.9 are independently selected from H, CH.sub.3, C.sub.1-C.sub.10 alkyl, alkenyl, alkylol, alkoxy, and alkylamine. 5. The compound of claim 4, wherein said alicyclic, aromatic, or heterocyclic ring system is a cyclopentyl ring, a cyclohexyl ring, a phenyl ring or a pyridyl ring. 6. The compound of claim 4, wherein said compound is selected from the group consisting of: a) 3-methyl-6-phenylselenopheno[3,2-d]1,2,3-triazin-4-one; b) 6-(tert-butyl)-3-methylselenopheno[3,2-d]1,2,3-triazin-4-one; 3-methyl-6,7,8,9-tetrahydrobenzo[1,2-b]1,2,3-triazino[4,5-d]selenophen-4-- one; d) 3-methyl-1,2,3-triazino[4',5'-5,4]selenopheno[2,3-b]pyridine-4-one- ; and e) 3-methylbenzo[b]1,2,3-triazino[4,5-d]selenophen-4-one. 7. A pharmaceutical composition comprising at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, in combination with at least one selected from pharmaceutically acceptable excipient, pharmaceutically acceptable diluent, and pharmaceutically acceptable carrier. 8. A pharmaceutical composition comprising at least one compound of claim 4 or a pharmaceutically acceptable salt thereof, in combination with at least one selected from pharmaceutically acceptable excipient, pharmaceutically acceptable diluent, and pharmaceutically acceptable carrier. 9. A pharmaceutical composition according to claim 7, further comprising at least one compound of formula (II) having a selenophene ring or a pharmaceutically acceptable salt thereof: ##STR00038## wherein: the notation represents a single bond or a double bond; X, Y and Z are independently selected from C and Se so as to form a selenophene ring, with the proviso that a double bond is either in between X and Y or in between Y and Z; R.sup.6 and BY are either: a) independently selected from H, N.dbd.N--N(CH.sub.3).sub.2, N.dbd.N--NHCH.sub.3, N.dbd.N--N(CH.sub.3)CH.sub.2OH, CONH.sub.2, CONHR.sup.8, CONR.sup.8R.sup.9, CONHNH.sub.2, CONHNHR.sup.8, CONHNR.sup.8R.sup.9, COOCH.sub.3, COOCH.sub.2CH.sub.3, COOH, COSH, CN, CECH, SO.sub.2NH.sub.2, SO.sub.2NHR.sup.8, SO.sub.2NR.sup.8R.sup.9, NO.sub.2, CF.sub.3, Cl, Br, F, CCl.sub.3, CH.sub.3, OH, OCH.sub.3, SH, SCH.sub.3, NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, alkyl, alkenyl, electron withdrawing functional groups, and electron donating functional groups; or b) joined together to form an alicyclic, aromatic, or heterocyclic ring system which is fused to two adjacent carbon atoms in said selenophene ring; and R.sup.8 and R.sup.9 are independently selected from H, CH.sub.3, C.sub.1-C.sub.10 alkyl, alkenyl, alkylol, alkoxy, and alkylamine. 10. A pharmaceutical composition comprising at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, further comprising at least one chemotherapeutic agent in combination with at least one selected from pharmaceutically acceptable excipient, pharmaceutically acceptable diluent, and pharmaceutically acceptable carrier. 11. The pharmaceutical composition of claim 8, further comprising at least one chemotherapeutic agent. 12. The pharmaceutical composition of claim 9, further comprising at least one chemotherapeutic agent. 13. The composition as claimed in claim 10, wherein said chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, 6-mercaptopurine, actinomycin, doxorubicin, aminoglutethimide, anastrozole, bevacizumab, bleomycin, carboplatin, cactinomycin, capecitabine, cisplatin, clodronic acid, cyclophosphamide, dactinomycin, docetaxel, doxorubicin, epirubicin, etoposide, exemestane, fluorouracil, fluoxymesterone, letrozole, leucovorin calcium, megestrol, megestrol acetate, methotrexate, mitomycin, mitoxantrone, paclitaxel, pamidronate, prednisone, tamoxifen, trastuzumab, thiotepa, vinblastine, vincristine, vinorelbine, pharmaceutically acceptable salts thereof, and mixtures thereof. 14. The composition as claimed in claim 11, wherein said chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, 6-mercaptopurine, actinomycin, doxorubicin, aminoglutethimide, anastrozole, bevacizumab, bleomycin, carboplatin, cactinomycin, capecitabine, cisplatin, clodronic acid, cyclophosphamide, dactinomycin, docetaxel, doxorubicin, epirubicin, etoposide, exemestane, fluorouracil, fluoxymesterone, letrozole, leucovorin calcium, megestrol, megestrol acetate, methotrexate, mitomycin, mitoxantrone, paclitaxel, pamidronate, prednisone, tamoxifen, trastuzumab, thiotepa, vinblastine, vincristine, vinorelbine, pharmaceutically acceptable salts thereof, and mixtures thereof. 15. The composition as claimed in claim 12, wherein said chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, 6-mercaptopurine, actinomycin, doxorubicin, aminoglutethimide, anastrozole, bevacizumab, bleomycin, carboplatin, cactinomycin, capecitabine, cisplatin, clodronic acid, cyclophosphamide, dactinomycin, docetaxel, doxorubicin, epirubicin, etoposide, exemestane, fluorouracil, fluoxymesterone, letrozole, leucovorin calcium, megestrol, megestrol acetate, methotrexate, mitomycin, mitoxantrone, paclitaxel, pamidronate, prednisone, tamoxifen, trastuzumab, thiotepa, vinblastine, vincristine, vinorelbine, pharmaceutically acceptable salts thereof, and mixtures thereof. 16. A pharmaceutical composition comprising at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, further comprising: at least one agent selected from the group consisting of monoclonal antibodies, interferons, interleukins, colony stimulating factors, and TNF-.alpha. receptor blocker drugs, in combination with at least one component selected from pharmaceutically acceptable excipients, pharmaceutically acceptable diluents, and pharmaceutically acceptable carriers. 17. The pharmaceutical composition of claim 8, further comprising at least one agent selected from the group consisting of monoclonal antibodies, interferons, interleukins, colony stimulating factors, and TNF-.alpha. receptor blocker drugs. 18. The pharmaceutical composition of claim 9, further comprising at least one agent selected from the group consisting of monoclonal antibodies, interferons, interleukins, colony stimulating factors, and TNF-.alpha. receptor blocker drugs. 19. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors in a warm blooded animal suffering from such disease, wherein said method comprises administering to the said warm blooded animal a therapeutically effective amount of at least one compound according to claim 1. 20. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors in a warm blooded animal suffering from such disease, wherein said method comprises administering to the said warm blooded animal a therapeutically effective amount of at least one compound according to claim 4, alone or in combination with a compound of formula (I) having a selenophene ring or a pharmaceutically acceptable salt thereof: ##STR00039## wherein: R is selected from H, CH.sub.3 and CH.sub.2OH; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from the group consisting of H, N.dbd.N--N(CH.sub.3).sub.2, N.dbd.N--NHCH.sub.3, N.dbd.NN(CH.sub.3)CH.sub.2OH, CONH.sub.2, CONHR.sup.4, CONR.sup.4R.sup.5, CONHNH.sub.2, CONHNHR.sup.4, CONHNR.sup.4R.sup.5, COOCH.sub.3, COOCH.sub.2CH.sub.3, COOH, COSH, CN, C.ident.CH, SO.sub.2NH.sub.2, SO.sub.2NHR.sup.4, SO.sub.2NR.sup.4R.sup.5, NO.sub.2, CF.sub.3, Cl, Br, F, CCl.sub.3, CH.sub.3, OH, OCH.sub.3, SH, SCH.sub.3, NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, alkyl, alkenyl, electron withdrawing functional groups and electron donating functional groups, wherein R.sup.4 and R.sup.5 are independently selected from the group consisting of H, CH.sub.3, C.sub.1-C.sub.10 alkyl, alkenyl, alkylol, alkoxy, and alkylamine; or any two of R.sup.1, R.sup.2 and R.sup.3 are joined together to form a ring selected from the group consisting of an alicyclic, aromatic, or heterocyclic ring system which is fused to two adjacent carbon atoms in said selenophene ring. 21. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors in a warm blooded animal suffering from such disease, wherein said method comprises administering to the said warm blooded animal a therapeutically effective amount of at least one compound according to claim 1 in combination with at least one additive selected from the group consisting of pharmaceutically acceptable excipients, pharmaceutically acceptable diluents and pharmaceutically acceptable carriers; at least one optional chemotherapeutic agent; and at least one optional agent selected from the group consisting of monoclonal antibodies, interferons, interleukins, colony stimulating factors, and TNF-.alpha. receptor blocker drugs. 22. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors in a warm blooded animal suffering from such disease, wherein said method comprises administering to the said warm blooded animal a composition comprising a therapeutically effective amount of at least one compound according to claim 4; wherein said composition further comprises: at least one additive selected from the group consisting of pharmaceutically acceptable excipients, pharmaceutically acceptable diluents and pharmaceutically acceptable carriers; an optional chemotherapeutic agent; an optional agent selected from the group consisting of monoclonal antibodies, interferons, interleukins, colony stimulating factors, and TNF-.alpha. receptor blacker drugs; and an optional compound of formula (I) having a selenophene ring or a pharmaceutically acceptable salt thereof: ##STR00040## wherein: R is selected from H, CH.sub.3 and CH.sub.2OH; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from the group consisting of H, N.dbd.N--N(CH.sub.3).sub.2, N.dbd.N--NHCH.sub.3, N.dbd.NN(CH.sub.3)CH.sub.2OH, CONH.sub.2, CONHR.sup.4, CONR.sup.4R.sup.5, CONHNH.sub.2, CONHNHR.sup.4, CONHNHR.sup.4R.sup.5, COOCH.sub.3, COOCH.sub.2CH.sub.3, COOH, COSH, CN, CECH, SO.sub.2NH.sub.2, SO.sub.2NHR.sup.4, SO.sub.2NR.sup.4R.sup.5, NO.sub.2, CF.sub.3, Cl, Br, F, CCl.sub.3, CH.sub.3, OH, OCH.sub.3, SH, SCH.sub.3, NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, alkyl, alkenyl, electron withdrawing functional groups and electron donating functional groups, wherein R.sup.4 and R.sup.5 are independently selected from the group consisting of H, CH.sub.3, C.sub.1-C.sub.10 alkyl, alkenyl, alkylol, alkoxy, and alkylamine; or any two of R.sup.1, R.sup.2 and R.sup.3 are joined together to form a ring selected from the group consisting of an alicyclic, aromatic, or heterocyclic ring system which is fused to two adjacent carbon atoms in said selenophene ring. 23. The method of claim 20, wherein any two of R.sup.1, R.sup.2 and R.sup.3 are joined together to form a ring selected from the group consisting of said alicyclic, aromatic, or heterocyclic ring system, said ring system being a cyclopentyl ring, a cyclohexyl ring, a phenyl ring or a pyridyl ring. 24. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors in a warm blooded animal suffering from such diseases, wherein the method comprises administering at least one compound or a pharmaceutically acceptable salt thereof as claimed in claim 1, in conjunction with a means of therapy selected from the group consisting of antiangiogenesis therapy, chemotherapy, cytokine therapy, radiotherapy, gene therapy, hormonal therapy, surgery, vaccination, and a combination thereof. 25. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors in a warm blooded animal suffering from such disease, wherein the method comprises administering at least one compound or a pharmaceutically acceptable salt thereof as claimed in claim 4, in conjunction with a means of therapy selected from the group consisting of anti-angiogenesis therapy, chemotherapy, cytokine therapy, radiotherapy, gene therapy, hormonal therapy, surgery, vaccination, and a combination thereof. 26. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors as claimed in claim 19, wherein the said administration comprises the routes selected from the group consisting of intraperitoneal (IP), intravenous (IV), oral (PO), intramuscular (TM), intracutaneous (IC), intradermal (ID), intrauterine, intratumoral and intrarectal. 27. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors as claimed in claim 20, wherein the said administration comprises the routes selected from the group consisting of intraperitoneal (IP), intravenous (IV), oral (PO), intramuscular (IM), intracutaneous (IC), intradermal (ID), intrauterine, intratumoral and intrarectal. 28. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors as claimed in claim 19, wherein the said administration comprises administering the compounds through a dosage form selected from Liposome-based, Polymeric surfactant-based, Biodegradable block copolymers, Microencapsulation and Nanoparticles to said warm blooded animal. 29. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors as claimed in claim 20, wherein the said administration comprises administering the compounds through a dosage form selected from Liposome-based, Polymeric surfactant-based, Biodegradable block copolymers, Microencapsulation and Nanoparticles to said warm blooded animal. 30. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors in a warm blooded animal suffering from such disease, wherein said method comprises administering to the said warm blooded animal a therapeutically effective amount of at least one compound selected from the group consisting of: a) 4-[(dimethylamino)diazenyl]-5-methylselenophene-2-carboxamide; b) 3-[(dimethylamino)diazenyl]selenophene-2,5-dicarboxamide; c) 3-[(dimethylamino)diazenyl]-5-phenylselenophene-2-carboxamide; d) 3-[(dimethylamino) diazenyl]-5-(tert-butyl) selenophene-2-carboxamide; e) 3-[(dimethylamino)diazenyl]-4,5,6,7-tetrahydrobenzo[1,2-b]selenophene-2-c- arboxamide; f) 3-[(dimethylamino) diazenyl]selenopheno [2,3-b]pyridine-2-carboxamide g) 3-[(dimethylamino)diazenyl]-5-phenylselenophene-2-carboxylic acid; h) 3-[(dimethylamino)diazenyl]-5-(tert-butyl)selenophene-2-carboxylic acid; i) 3-[(dimethylamino)diazenyl]-4,5,6,7-tetrahydrobenzo[1,2-b]selenophene-- 2-carboxylic acid; j) 3-[(dimethylamino)diazenyl]selenopheno[2,3-b]pyridine-2-carboxylic acid; k) 3-[(dimethylamino)diazenyl]-5-(tert-butyl)selenophene-2-carbonitrile; l) 3-methyl-6-phenylselenopheno[3,2-d]1,2,3-triazin-4-one; m) 6-(tert-butyl)-3-methylselenopheno[3,2-d]1,2,3-triazin-4-one; n) 3-methyl-6,7,8,9-tetrahydrobenzo[1,2-b]1,2,3-triazino[4,5-d]selenophen-4-- one; o) 3-methyl-1,2,3-triazino[4',5'-5,4]selenopheno[2,3-b]pyridine-4-one- ; and p) 3-methylbenzo[b]1,2,3-triazino[4,5-d]selenophen-4-one. 31. A method of treating a disease selected from the group consisting of melanoma, lung tumors, prostate tumors, colon cancer, and breast tumors in a warm blooded animal suffering from such disease in need thereof, wherein said method comprises administering to the said warm blooded animal, a composition comprising a therapeutically effective amount of at least one compound according to claim 30 or a pharmaceutically acceptable salt thereof, in combination with at least one selected from pharmaceutically acceptable excipients, pharmaceutically acceptable diluents and pharmaceutically acceptable carriers, optionally comprising at least one chemotherapeutic agent, further optionally comprising at least one biologic response, agent selected from the group consisting of monoclonal antibodies, interferons, interleukins, colony stimulating factors and TNF-.alpha. receptor for blocker drugs.

Details for Patent 8,143,237

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2029-04-27
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2029-04-27
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2029-04-27
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2029-04-27